A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin

mAbs

Volumn 3, Issue 3, 2011, Pages 264-272

  Villa, Alessandra ^a   Lovato, Valeria ^a   Bujak, Emil ^a   Wulhfard, Sarah ^a   Pasche, Nadine ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Chelating recombinant antibody (CRAb); Human antibody library; Oncofetal fibronectin; Phage display; scFv antibody fragments; Vascular tumor targeting

Indexed keywords

ANTIBODY; CHELATING AGENT; EPITOPE; FIBRONECTIN; IMMUNOGLOBULIN HEAVY CHAIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F8; OCRELIZUMAB; ONCOFETAL ANTIGEN; RECOMBINANT ANTIBODY; SERINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY ISOLATION; ANTIBODY LIBRARY; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; GERM LINE; HYDROPHILICITY; MOUSE; NONHUMAN; PHAGE DISPLAY; PROTEIN DOMAIN; TERATOCARCINOMA;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BASE SEQUENCE; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; EPITOPES; FEMALE; FIBRONECTINS; HUMANS; MICE; MICE, 129 STRAIN; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PEPTIDE LIBRARY; SINGLE-CHAIN ANTIBODIES; TISSUE DISTRIBUTION;

EID: 79955650818     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.3.15616     Document Type: Article

References (65)

1. Walsh G. Biopharmaceutical benchmarks 2006. Nat Biotechnol 2006; 24:769-76.
2. Walsh G. Biopharmaceutical benchmarks 2010. Nat Biotechnol 2010; 28:917-24.
3. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994; 12:433-55.
4. Hoogenboom HR, Winter G. By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J Mol Biol 1992; 227:381-8.
5. Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, Lane D, et al. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J 1994; 13:692-8.
6. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 1994; 13:3245-60. (Pubitemid 24226939)
7. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996; 14:309-14.
8. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 2000; 296:57-86.
9. Soderlind E, Strandberg L, Jirholt P, Kobayashi N, Alexeiva V, Aberg AM, et al. Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat Biotechnol 2000; 18:852-6. (Pubitemid 30640910)
10. O'Connell D, Becerril B, Roy-Burman A, Daws M, Marks JD. Phage versus phagemid libraries for generation of human monoclonal antibodies. J Mol Biol 2002; 321:49-56. (Pubitemid 34948468)
11. Silacci M, Brack S, Schirru G, Marlind J, Ettorre A, Merlo A, et al. Design, construction and characterization of a large synthetic human antibody phage display library. Proteomics 2005; 5:2340-50. (Pubitemid 40835403)
12. den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002; 29:2288-98. (Pubitemid 35266018)
13. Schliemann C, Neri D. Antibody-based vascular tumor targeting. Recent Results Cancer Res 2010; 180:201-16.
14. Schliemann C, Neri D. Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta 2007; 1776:175-92. (Pubitemid 350061071)
15. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, et al. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 2008; 122:2405-13. (Pubitemid 351590471)
16. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998; 273:21769-76. (Pubitemid 28405353)
17. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 1999; 59:347-52. (Pubitemid 29048866)
18. Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, et al. A high-affinity human antibody that targets tumoral blood vessels. Blood 1999; 94:192-8. (Pubitemid 29300149)
19. Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006; 12:3200-8. (Pubitemid 43837370)
20. Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D. Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 2009; 33:1718-22.
21. Viti F, Nilsson F, Demartis S, Huber A, Neri D. Design and use of phage display libraries for the selection of antibodies and enzymes. Methods Enzymol 2000; 326:480-505.
22. Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G. The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol 1992; 227:776-98.
23. Williams SC, Frippiat JP, Tomlinson IM, Ignatovich O, Lefranc MP, Winter G. Sequence and evolution of the human germline Vlambda repertoire. J Mol Biol 1996; 264:220-32. (Pubitemid 26402693)
24. Cox JP, Tomlinson IM, Winter G. A directory of human germ-line Vkappa segments reveals a strong bias in their usage. Eur J Immunol 1994; 24:827-36.
25. Silacci M, Brack SS, Spath N, Buck A, Hillinger S, Arni S, et al. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel 2006; 19:471-8. (Pubitemid 44408907)
26. Ettorre A, Rosli C, Silacci M, Brack S, McCombie G, Knochenmuss R, et al. Recombinant antibodies for the depletion of abundant proteins from human serum. Proteomics 2006; 6:4496-505. (Pubitemid 44339438)
27. Ahlskog JK, Schliemann C, Marlind J, Qureshi U, Ammar A, Pedley RB, et al. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer 2009; 101:645-57.
28. Pfaffen S, Hemmerle T, Weber M, Neri D. Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3. Exp Cell Res 2010; 316:836-47.
29. Sgier D, Zuberbuehler K, Pfaffen S, Neri D. Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA. Protein Eng Des Sel 2010; 23:261-9.
30. Piazza T, Cha E, Bongarzone I, Canevari S, Bolognesi A, Polito L, et al. Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody. J Cell Sci 2005; 118:1515-25. (Pubitemid 40585131)
31. Avignolo C, Bagnasco L, Biasotti B, Melchiori A, Tomati V, Bauer I, et al. Internalization via Antennapedia protein transduction domain of an scFv antibody toward c-Myc protein. FASEB J 2008; 22:1237-45. (Pubitemid 351519977)
32. Lovato V, Roesli C, Ahlskog J, Scheuermann J, Neri D. A monoclonal antibody prevents aggregation of the NBD1 domain of the cystic fibrosis transmembrane conductance regulator. Protein Eng Des Sel 2007; 20:607-14.
33. Kirkham PM, Neri D, Winter G. Towards the design of an antibody that recognises a given protein epitope. J Mol Biol 1999; 285:909-15. (Pubitemid 29054305)
34. Neri D, Momo M, Prospero T, Winter G. High-affinity antigen binding by chelating recombinant antibodies (CRAbs). J Mol Biol 1995; 246:367-73.
35. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 2005; 10:1237-44. (Pubitemid 41411434)
36. Wright MJ, Deonarain MP. Phage display of chelating recombinant antibody libraries. Mol Immunol 2007; 44:2860-9. (Pubitemid 46412503)
37. Ewert S, Huber T, Honegger A, Pluckthun A. Biophysical properties of human antibody variable domains. J Mol Biol 2003; 325:531-53. (Pubitemid 36062681)
38. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988; 85:5879-83.
39. Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int J Cancer 2006; 118:1331-9.
40. Ffrench-Constant C, Van de Water L, Dvorak HF, Hynes RO. Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J Cell Biol 1989; 109:903-14. (Pubitemid 19197047)
41. Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 2009; 11:142.
42. Frey K, Schliemann C, Schwager K, Giavazzi R, Johannsen M, Neri D. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. J Urol 2010; 184:2540-8.
43. Kaspar M, Trachsel E, Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 2007; 67:4940-8. (Pubitemid 46910202)
44. Sommavilla R, Pasche N, Trachsel E, Giovannoni L, Roesli C, Villa A, et al. Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12. Protein Eng Des Sel 2010; 23:653-61.
45. Trachsel E, Bootz F, Silacci M, Kaspar M, Kosmehl H, Neri D. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther 2007; 9:9.
46. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005; 5:436-46. (Pubitemid 40791486)
47. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009; 113:2265-74.
48. Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, et al. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 2010; 46:2926-35.
49. Dreier T, Baeuerle PA, Fichtner I, Grun M, Schlereth B, Lorenczewski G, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J Immunol 2003; 170:4397-402. (Pubitemid 36428210)
50. Gruen M, Bommert K, Bargou RC. T-cell-mediated lysis of B cells induced by a CD19 x CD3 bispecific single-chain antibody is perforin dependent and death receptor independent. Cancer Immunol Immunother 2004; 53:625-32. (Pubitemid 38858336)
51. Ren-Heidenreich L, Davol PA, Kouttab NM, Elfenbein GJ, Lum LG. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model. Cancer 2004; 100:1095-103. (Pubitemid 38222871)
52. FitzGerald K, Holliger P, Winter G. Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng 1997; 10:1221-5. (Pubitemid 28046183)
53. Holliger P, Manzke O, Span M, Hawkins R, Fleischmann B, Qinghua L, et al. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Res 1999; 59:2909-16. (Pubitemid 29283131)
54. McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, et al. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol 1999; 36:433-45. (Pubitemid 29336224)
55. McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, et al. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol 2001; 166:6112-7. (Pubitemid 32440739)
56. Haisma HJ, Grill J, Curiel DT, Hoogeland S, van Beusechem VW, Pinedo HM, et al. Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther 2000; 7:901-4. (Pubitemid 30437291)
57. Kontermann RE. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 2005; 26:1-9. (Pubitemid 40093233)
58. Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 2007; 13:3058-67. (Pubitemid 46849583)
59. Chan HS, Gallie BL, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos J, et al. MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 1997; 3:1699-706. (Pubitemid 27444707)
60. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991; 222:581-97.
61. Wulhfard S, Tissot S, Bouchet S, Cevey J, De Jesus M, Hacker DL, et al. Mild hypothermia improves transient gene expression yields several fold in Chinese hamster ovary cells. Biotechnol Prog 2008; 24:458-65. (Pubitemid 351520363)
62. Trussel S, Dumelin C, Frey K, Villa A, Buller F, Neri D. New strategy for the extension of the serum half-life of antibody fragments. Bioconjug Chem 2009; 20:2286-92.
63. Tomlinson IM, Cox JP, Gherardi E, Lesk AM, Chothia C. The structural repertoire of the human Vkappa domain. EMBO J 1995; 14:4628-38.
64. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, Winter G. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 1991; 19:4133-7. (Pubitemid 21912784)
65. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002; 102:75-85.